162 related articles for article (PubMed ID: 29760569)
1. Concomitant use of opioid medications with triptans or serotonergic antidepressants in US office-based physician visits.
Molina KC; Fairman KA; Sclar DA
Drug Healthc Patient Saf; 2018; 10():37-43. PubMed ID: 29760569
[TBL] [Abstract][Full Text] [Related]
2. Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome.
Sclar DA; Robison LM; Castillo LV; Schmidt JM; Bowen KA; Oganov AM; Skaer TL; Kogut SJ
Headache; 2012 Feb; 52(2):198-203. PubMed ID: 22289074
[TBL] [Abstract][Full Text] [Related]
3. Concomitant triptan and SSRI or SNRI use: a risk for serotonin syndrome.
Sclar DA; Robison LM; Skaer TL
Headache; 2008 Jan; 48(1):126-9. PubMed ID: 18005139
[TBL] [Abstract][Full Text] [Related]
4. Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome.
Orlova Y; Rizzoli P; Loder E
JAMA Neurol; 2018 May; 75(5):566-572. PubMed ID: 29482205
[TBL] [Abstract][Full Text] [Related]
5. Interaction between tramadol and selective serotonin reuptake inhibitors: are doctors aware of potential risks in their prescription practice?
Spies PE; Pot JLWH; Willems RPJ; Bos JM; Kramers C
Eur J Hosp Pharm; 2017 Mar; 24(2):124-127. PubMed ID: 31156918
[TBL] [Abstract][Full Text] [Related]
6. Association of co-prescribing of opioid and benzodiazepine substitutes with incident falls and fractures among older adults: a cohort study.
Shah R; Raji MA; Westra J; Kuo YF
BMJ Open; 2021 Dec; 11(12):e052057. PubMed ID: 35476819
[TBL] [Abstract][Full Text] [Related]
7. Co-prescribing of Central Nervous System-Active Medications for COPD Patients: Impact on Emergency Room Visits and Hospitalization.
Sood A; Kuo YF; Westra J; Sharma G; Raji MA
Ann Pharmacother; 2023 Apr; 57(4):382-396. PubMed ID: 35942598
[TBL] [Abstract][Full Text] [Related]
8. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
[TBL] [Abstract][Full Text] [Related]
9. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper.
Evans RW; Tepper SJ; Shapiro RE; Sun-Edelstein C; Tietjen GE
Headache; 2010 Jun; 50(6):1089-99. PubMed ID: 20618823
[TBL] [Abstract][Full Text] [Related]
10. Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks.
Lee JH; Shewale AR; Barthold D; Devine B
Headache; 2021 Nov; 61(10):1499-1510. PubMed ID: 34841520
[TBL] [Abstract][Full Text] [Related]
11. What factors influence the prescribing of antidepressant pharmacotherapy? An assessment of national office-based encounters.
Sclar DA; Robison LM; Skaer TL; Galin RS
Int J Psychiatry Med; 1998; 28(4):407-19. PubMed ID: 10207740
[TBL] [Abstract][Full Text] [Related]
12. Identifying the factors underlying discontinuation of triptans.
Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
[TBL] [Abstract][Full Text] [Related]
13. Trends and prescribing patterns of antimigraine medicines in nine major cities in China from 2018 to 2022: a retrospective prescription analysis.
Huang J; Wang X; Jin Y; Lou G; Yu Z
J Headache Pain; 2024 Apr; 25(1):62. PubMed ID: 38654177
[TBL] [Abstract][Full Text] [Related]
14. The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and Triptans: an analysis of the 29 case reports.
Evans RW
MedGenMed; 2007 Sep; 9(3):48. PubMed ID: 18092054
[TBL] [Abstract][Full Text] [Related]
15. Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDA's alert warranted?
Wenzel RG; Tepper S; Korab WE; Freitag F
Ann Pharmacother; 2008 Nov; 42(11):1692-6. PubMed ID: 18957623
[TBL] [Abstract][Full Text] [Related]
16. Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients.
Tepper S; Allen C; Sanders D; Greene A; Boccuzzi S
Headache; 2003 Jan; 43(1):44-8. PubMed ID: 12864757
[TBL] [Abstract][Full Text] [Related]
17. Onset of Transient Sadness Following the Concomitant Use of a Triptan and Selective Serotonin Reuptake Inhibitor/Serotonin Norepinephrine Reuptake Inhibitors Therapy: A Case Report.
Meng Y; Yuen J
J Pharm Pract; 2023 Jun; 36(3):705-710. PubMed ID: 34962845
[No Abstract] [Full Text] [Related]
18. Adherence to Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Prescriptions Affects Overall Medication Adherence in Older Persons: Evidence From the Italian Nationwide OsMed Health-DB Database.
Marengoni A; Onder G; Degli Esposti L; Russo P; Sangiorgi D; Buda S; Fini M; Marchionni N; Bonassi S; Mammarella F; Marrocco W; Pozzi G; Palmer K; Monaco A; Pecorelli S; Pani L;
J Clin Psychiatry; 2016 Dec; 77(12):1712-1718. PubMed ID: 28086009
[TBL] [Abstract][Full Text] [Related]
19. Risk of Poor Neonatal Adaptation Syndrome Among Infants Exposed to Second-Generation Atypical Antipsychotics Compared to Antidepressants: Results From the National Pregnancy Registry for Psychiatric Medications.
Viguera AC; McElheny SA; Caplin PS; Kobylski LA; Rossa ET; Young AV; Gaccione P; Góez-Mogollón L; Freeman MP; Cohen LS
J Clin Psychiatry; 2023 Jan; 84(1):. PubMed ID: 36602927
[No Abstract] [Full Text] [Related]
20. Drug Interaction and Serotonin Toxicity with Opioid Use: Another Reason to Avoid Opioids in Headache and Migraine Treatment.
Ansari H; Kouti L
Curr Pain Headache Rep; 2016 Aug; 20(8):50. PubMed ID: 27457368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
